Recombinant activated factor VII: mechanisms of action and current indications

Seminars in Thrombosis and Hemostasis
Massimo Franchini, Giuseppe Lippi

Abstract

Recombinant activated factor VII (rFVIIa) was initially developed to overcome the limitations of existing treatments for patients with congenital hemophilia and inhibitors. Clinical success in this arena led to experimental use in other coagulopathies characterized by impaired thrombin generation, and approval for use in acquired hemophilia, factor VII deficiency, and Glanzmann's thrombasthenia soon followed. Extensive research and growing experience in the clinical setting has increased our knowledge of rFVIIa and improved our understanding of how its mechanism of action leads to effective bleeding control. This article reviews current understanding of the mechanisms of action of rFVIIa before providing a brief overview of clinical experience to date in its licensed indications. The agent's safety profile is also examined, along with recent advances in rFVIIa dosing and storage that may help to improve both clinical outcomes and patient quality of life.

Citations

Nov 6, 2010·Journal of Thrombosis and Thrombolysis·Massimo Franchini, Giuseppe Lippi
Oct 30, 2012·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Bulent AliogluYildiz Dallar
Aug 9, 2012·Current Opinion in Hematology·Loan Hsieh, Diane Nugent
Aug 29, 2012·Obstetrical & Gynecological Survey·Kiran Prabhaker RaoJoseph A Spinnato
Jul 3, 2013·Blood Reviews·Massimo Franchini, Pier Mannuccio Mannucci
Sep 7, 2013·Thrombosis and Haemostasis·Massimo Franchini, Pier Mannuccio Mannucci
Jan 6, 2011·British Journal of Clinical Pharmacology·Massimo Franchini, Pier Mannuccio Mannucci
Feb 5, 2013·British Journal of Haematology·Douglas W Sborov, George M Rodgers
Mar 19, 2014·British Journal of Haematology·Massimo Franchini, Pier Mannuccio Mannucci
Jul 13, 2014·Journal of Thrombosis and Thrombolysis·Massimo FranchiniCarlo Bonfanti
Apr 27, 2017·Hematology·Massimo FranchiniGiancarlo Maria Liumbruno
Jan 20, 2011·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Giuseppe LippiMassimo Franchini
Dec 24, 2018·Expert Review of Hematology·Christine Biron-Andreani, Jean-François Schved
Mar 16, 2012·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalGeorgia Salanti
Apr 15, 2020·Expert Review of Hematology·Massimo FranchiniGiancarlo Maria Liumbruno
May 26, 2018·Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko·A Yu Lubnin
Mar 4, 2021·Expert Review of Hematology·Massimo FranchiniGiancarlo Maria Liumbruno
Aug 7, 2021·Annals of Emergency Medicine·Kelly Johnson-Arbor, Richard Verstraete

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Haemophilia : the Official Journal of the World Federation of Hemophilia
A ObergfellM Ezban
Seminars in Thrombosis and Hemostasis
Caroline Cromwell, L Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia
P Margaritis, K A High
Seminars in Thrombosis and Hemostasis
Massimo FranchiniGiuseppe Lippi
© 2021 Meta ULC. All rights reserved